Smoking Addiction - Pipeline Review, H2 2016

 

Rating

4.5 Star Rating for report Smoking Addiction - Pipeline Review, H2 2016
4.5 / 5 stars rating
Pages: 111
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H2 2016, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8907IDBMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-Sys...Dec 2016
Report... 05IB-GMDHC8884IDBProgressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8855IDBProgressive Supranuclear Palsy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8845IDBMultiple Sclerosis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-21 

Report: Smoking Addiction - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Smoking Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Smoking Addiction - Overview 10
Pipeline Products for Smoking Addiction - Comparative Analysis 11
Smoking Addiction - Therapeutics under Development by Companies 12
Smoking Addiction - Therapeutics under Investigation by Universities/Institutes 14
Smoking Addiction - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Smoking Addiction - Products under Development by Companies 18
Smoking Addiction - Products under Investigation by Universities/Institutes 19
Smoking Addiction - Companies Involved in Therapeutics Development 20
Aradigm Corp 20
Arena Pharmaceuticals Inc 21
Astraea Therapeutics LLC 22
Bioprojet SCR 23
CoMentis Inc 24
Embera NeuroTherapeutics Inc 25
Euthymics Bioscience Inc 26
Invion Ltd 27
Jeil Pharmaceutical Co Ltd 28
Johnson & Johnson 29
Lotus Pharmaceutical Co Ltd 30
Marinus Pharmaceuticals Inc 31
NAL Pharmaceuticals Ltd 32
Pfizer Inc 33
Selecta Biosciences Inc 34
Seoul Pharma Co Ltd 35
Zynerba Pharmaceuticals Inc 36
Smoking Addiction - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(metyrapone + oxazepam) - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AKR-214 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
amitifadine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Anatabine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AT-1001 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BP-1.4979 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ganaxolone - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GTS-21 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
JLP-1603 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
JNJ-39393406 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
lorcaserin hydrochloride - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
nadolol - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
NFL-101 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
NIC-7DT - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
nicotine bitartrate - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
nicotine bitartrate - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Nicotine Vaccine - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
PF-06413367 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
SEL-070 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SPO-1105 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
URB-694 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Smoking Addiction - Dormant Projects 95
Smoking Addiction - Discontinued Products 97
Smoking Addiction - Product Development Milestones 98
Featured News & Press Releases 98
Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis 98
Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation 99
Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation 100
Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation 101
Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 102
Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 103
Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 103
Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 104
May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 105
Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol) 105
Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 106
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 106
Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 107
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 108
Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111
 

List of Tables

List of Tables
Number of Products under Development for Smoking Addiction, H2 2016 10
Number of Products under Development for Smoking Addiction - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Comparative Analysis by Unknown Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Smoking Addiction - Pipeline by Aradigm Corp, H2 2016 20
Smoking Addiction - Pipeline by Arena Pharmaceuticals Inc, H2 2016 21
Smoking Addiction - Pipeline by Astraea Therapeutics LLC, H2 2016 22
Smoking Addiction - Pipeline by Bioprojet SCR, H2 2016 23
Smoking Addiction - Pipeline by CoMentis Inc, H2 2016 24
Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2016 25
Smoking Addiction - Pipeline by Euthymics Bioscience Inc, H2 2016 26
Smoking Addiction - Pipeline by Invion Ltd, H2 2016 27
Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 28
Smoking Addiction - Pipeline by Johnson & Johnson, H2 2016 29
Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 30
Smoking Addiction - Pipeline by Marinus Pharmaceuticals Inc, H2 2016 31
Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H2 2016 32
Smoking Addiction - Pipeline by Pfizer Inc, H2 2016 33
Smoking Addiction - Pipeline by Selecta Biosciences Inc, H2 2016 34
Smoking Addiction - Pipeline by Seoul Pharma Co Ltd, H2 2016 35
Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Assessment by Combination Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Smoking Addiction - Dormant Projects, H2 2016 95
Smoking Addiction - Dormant Projects (Contd..1), H2 2016 96
Smoking Addiction - Discontinued Products, H2 2016 97
 

List of Figures

List of Figures
Number of Products under Development for Smoking Addiction, H2 2016 10
Number of Products under Development for Smoking Addiction - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Top 10 Targets, H2 2016 39
Number of Products by Stage and Top 10 Targets, H2 2016 39
Number of Products by Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Types, H2 2016 45
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 7, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Central Nervous System 
Pages: 111 

Companies Featured

Aradigm Corp Arena Pharmaceuticals Inc Astraea Therapeutics LLC Bioprojet SCR CoMentis Inc Embera NeuroTherapeutics Inc Euthymics Bioscience Inc Invion Ltd Jeil Pharmaceutical Co Ltd Johnson & Johnson Lotus Pharmaceutical Co Ltd Marinus Pharmaceuticals Inc NAL Pharmaceuticals Ltd Pfizer Inc Selecta Biosciences Inc Seoul Pharma Co Ltd Zynerba Pharmaceuticals Inc

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8907IDBMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-Sys...Dec 2016
Report... 05IB-GMDHC8884IDBProgressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8855IDBProgressive Supranuclear Palsy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8845IDBMultiple Sclerosis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Smoking Addiction - Pipeline Review, H2 2016

Report 05IB-GMDHC8832IDB has a rating of 89 percent
Figure of merit assessment for report 05IB-GMDHC8832IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7188

Taxonomy Location

The taxonomy on the left shows the ancestors of the Central Nervous System node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Central Nervous System

Central Nervous System

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Smoking Addiction - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8832IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [0.20773s]

--